GE HealthCare Invests $138 Million in Cork, Ireland Manufacturing Facility to Address Increasing Contrast Media Demand
GE HealthCare (Nasdaq: GEHC) today announced a $138 million investment to expand its Carrigtohill, Cork contrast media fill and finish manufacturing site in Ireland. A new state-of-the-art facility on the grounds of the existing site will enable 25 million more patient doses per year of contrast media by the end of 2027, helping address growing global demand.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250130241464/en/
GE HealthCare’s contrast media manufacturing site in Cork (Photo: Business Wire)
Contrast media are injectable diagnostic imaging agents used to enhance visualization of organs, blood vessels and tissues during medical imaging. Global demand for iodine-based contrast media, used in X-Ray, Computed Tomography (CT) and Interventional procedures is expected to double in the next decade, driven by ageing populations and the increasing global prevalence of chronic disorders. In 2024, the Carrigtohill facility, along with GE HealthCare’s other fill and finish production sites in Shanghai, China, and Oslo, Norway, supplied over 100 million patient doses of contrast media around the worldiii.
The new 3000m2 facility - which will support both established and pipeline products – will include solution preparation vessels, multi-functional powder handling systems, a new filling line and autoclaves, with advanced automation systems underpinning production. Once established, the additional capacity will cater for the growing global demand, while offering increased flexibility and resiliency across GE HealthCare’s contrast media production network for security of supply.
President & CEO of GE HealthCare’s Pharmaceutical Diagnostics (PDx) segment, Kevin O’Neill, said, “As an industry leader we have a responsibility to help meet the growing global demand for contrast media from healthcare providers and their patients. This new facility demonstrates our broader commitment not just to address future demand, but also to increase resiliency and security of industry supply for customers.”
Eugene Barrett, Site Leader and Managing Director, GE HealthCare Ireland, said: “This expansion strengthens our longstanding presence in Cork, where we have a highly skilled team, access to leading talent in the pharmaceutical industry, strong distribution links around the world and a great partnership with IDA Ireland. First doses from our new facility are expected by the end of 2027 and we are proud of the impact our site will continue to make for patients around the world.”
An Taoiseach Micheál Martin T.D. said, “GE HealthCare has been manufacturing in Ireland for more than 30 years, and has invested extensively in the Carrigtohill site and the people working here. I am delighted to welcome this significant new investment here in Cork, which is testament to the commitment of GE HealthCare in Ireland, and also to our highly skilled workforce.”
IDA Ireland Executive Director Michael Lohan said, “This is the latest of GE HealthCare’s investments in its Cork site which has been producing vital pharmaceuticals for over 30 years. The continued growth and development of the site is testament to its commitment to serving patients and to Ireland’s leadership and support for the pharmaceutical industry.”
All stages of GE HealthCare’s contrast media manufacturing, from development of Active Pharmaceutical Ingredient (API) to finished product, adhere to Good Manufacturing Practices. With over 4000 employees globally, the PDx business also develops and supplies radiopharmaceuticals used to support diagnosis, monitoring and treatment selection across Neurology, Cardiology and Oncology clinical pathways. Across its portfolio, PDx enables four patient procedures every second globally.
Engineering firm, IPS-Integrated Project Services, will lead the project with enabling construction works starting at the Carrigtohill facility in February 2025, and over 250 construction roles expected to be created.
About GE HealthCare Technologies Inc.
GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are a $19.6 billion business with approximately 51,000 colleagues working to create a world where healthcare has no limits.
Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com for more information.
i GE HealthCare data on file – Cork Capacity Investment, 2025
ii GE HealthCare data on file – Pharmaceutical Diagnostics Contrast Media Capacity and Investment, 2025
iii GE HealthCare data on file – Pharmaceutical Diagnostics Contrast Media Capacity and Investment, 2025
View source version on businesswire.com: https://www.businesswire.com/news/home/20250130241464/en/
Contacts
GE HealthCare Media Contact:
David Morris
M +00 44 7920 591 370
David.j.morris@gehealthcare.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rimini Street Announces Fiscal Fourth Quarter and Annual 2024 Financial and Operating Results27.2.2025 23:01:00 EET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support and innovation solutions, the leading third-party support provider for Oracle, SAP and VMware software, today announced results for the 2024 fourth quarter and fiscal year ended December 31, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250227716952/en/ Rimini Street Announces Fiscal Fourth Quarter and Annual 2024 Financial and Operating Results (Graphic: Business Wire) Select Fourth Quarter 2024 Financial Results Revenue was $114.2 million for the 2024 fourth quarter, an increase of 1.9% compared to $112.1 million for the same period last year. U.S. revenue was $53.1 million for the 2024 fourth quarter, a decrease of 6.5% compared to $56.8 million for the same period last year. International revenue was $61.1 million for the 2024 fourth quarter, an increase of 10.5% compared to $55.3 million for the same period last year.
McKay Brothers Launches Fastest Connectivity Between Tokyo and Europe27.2.2025 23:00:00 EET | Press release
McKay Brothers International launched the lowest latency connectivity between key crypto trading hubs in Tokyo with those in London and Dublin. The new service achieves sub-132ms latency (round trip) between Tokyo and London. McKay’s Tokyo-London-Dublin service connects traders hosted in AWS in Tokyo and those trading at Equinix LD4 in London and AWS in Dublin. McKay’s newest route complements its existing ultra-low latency crypto connectivity from Tokyo to Hong Kong, Singapore, Chicago, and Ashburn. “Crypto trading increasingly demands low latency,” said Francois Tyc, MBI’s Managing Director. “We are pleased to leverage our many years of leadership in ultra-low latency connectivity for traditional finance to serve the fast growing low latency crypto market.” McKay previously leveraged existing infrastructure built for traditional finance connectivity to serve crypto traders. The new Tokyo-London-Dublin service is the company’s first ultra-low latency infrastructure developed exclusive
Everen Group Appoints James Peniston as Chief Investment Officer27.2.2025 20:00:00 EET | Press release
The Everen Group, a group of leading energy insurance companies based in Bermuda, is pleased to announce the appointment of James Peniston as Chief Investment Officer, effective April 1, 2025. His appointment follows the retirement of Ricky Lines and is part of a long-established succession plan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250227635764/en/ James Peniston (Photo: Business Wire) For the full release click here: https://everengroup.bm/everen-group-appoints-james-peniston-as-chief-investment-officer/ View source version on businesswire.com: https://www.businesswire.com/news/home/20250227635764/en/
Demetra Holding Spa Acquires Majority Stake in Swiss-based GetSet Surgical, Expanding Strategic Portfolio in the Spine Sector27.2.2025 19:43:00 EET | Press release
Demetra Holding, an innovative and independent international medical company leader in providing anti-infective cements, spacers and biomaterials for orthopedic applications, today announced its acquisition of a 51% stake in GetSet Surgical, a leading Swiss-based spine surgical solutions provider. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250227359973/en/ Michele Perrino, CEO of Demetra Holding (Photo: Business Wire) The acquisition marks a significant step in Demetra Holding's strategy to broaden its offerings in the Spine sector. The collaboration will combine Demetra’s existing technologies with GetSet’s expertise in sterile spine procedure kits, creating a comprehensive spinal/orthopedic product lineup designed to reduce infection risks, optimize hospital efficiency and contribute to environment sustainability. Strategic benefits of the acquisition This investment will integrate the strengths of both companies, esta
Riyadh International Disputes Week 2025 Concludes, With a High Turnout of Participants From 82 Countries27.2.2025 19:27:00 EET | Press release
Riyadh concluded the 2nd edition of the Riyadh International Disputes Week (RIDW25) with a significant international turnout of more than 4.8 thousand attendees from 82 countries. With more than 87 specialized legal events, RIDW25 featured 470 renowned local and international speakers, who came together to explore the latest global trends shaping the commercial dispute resolution industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250227533350/en/ With a rich lineup of legal and arbitration experts, lawyers, thought leaders, and representatives of key global organizations, the event reflects Saudi Arabia’s keenness to boost its investment climate, and attract foreign investment and major international companies, in charge of mega project developments in the Kingdom. Developing a wide range of dispute settlement mechanisms is a key factor in investment attractiveness and economic competitiveness globally. Organized by th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom